| Status | In progress |
| Decision | Selected |
| Process | STA 2018 |
| ID number | 3942 |
Provisional Schedule
| Expected publication | 17 August 2022 |
Project Team
| Project lead | Rebecca Richardson |
Email enquiries
- If you have any queries please email TAteam1@nice.org.uk
| External Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
| Companies sponsors | Gilead Sciences |
| Others | Department of Health and Social Care |
| NHE England and NHS Improvement | |
| Welsh Government | |
| Patient carer groups | Breast Cancer Now |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Eisai |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| BNF | |
| Department of Health, Social Services and public Safety - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare Products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 July 2022 - 28 July 2022 | Final draft guidance: 1 |
| 07 June 2022 | Committee meeting: 2 |
| 07 April 2022 - 29 April 2022 | Draft guidance: 1 |
| 27 April 2022 | Due to the number of topics on the agenda for the 10 May 2022 meeting and to allow a fuller discussion of the response to consultation, we have decided to reschedule the discussion of this topic to 7 June 2022. The Project team will contact you with details of how to register for the June meeting in due course |
| 15 March 2022 | Committee meeting: 1 |
| 17 August 2021 | Invitation to participate |
| 08 June 2021 - 06 July 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 30 January 2018 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual